Rankings
▼
Calendar
VTRS Q2 2023 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena
VTRS
Viatris Inc.
$17B
Q2 2023 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$3.9B
-4.8% YoY
Gross Profit
$1.6B
41.1% margin
Operating Income
$369M
9.4% margin
Net Income
$264M
6.7% margin
EPS (Diluted)
$0.22
QoQ Revenue Growth
+5.1%
Cash Flow
Operating Cash Flow
$525M
Free Cash Flow
$426M
Stock-Based Comp.
$39M
Balance Sheet
Total Assets
$48.7B
Total Liabilities
$27.9B
Stockholders' Equity
$20.8B
Cash & Equivalents
$629M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3.9B
$4.1B
-4.8%
Gross Profit
$1.6B
$1.7B
-5.6%
Operating Income
$369M
$549M
-32.7%
Net Income
$264M
$314M
-15.9%
Revenue Segments
Brands
$2.4B
63%
Generics
$1.3B
34%
Complex GX and Biosimilars
$139M
4%
Geographic Segments
Developed Markets Segment
$2.4B
60%
Emerging Markets Segment
$648M
17%
Greater China Segment
$532M
14%
Japan, Australia and New Zealand Segment
$376M
10%
← FY 2023
All Quarters
Q3 2023 →